Joanne Quan Sells 6,969 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 6,969 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $45.86, for a total value of $319,598.34. Following the sale, the insider now owns 5,649 shares in the company, valued at approximately $259,063.14. The trade was a 55.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Mirum Pharmaceuticals Trading Up 2.2 %

Shares of MIRM opened at $47.98 on Wednesday. The firm has a fifty day simple moving average of $43.48 and a two-hundred day simple moving average of $41.27. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $48.89. The stock has a market capitalization of $2.30 billion, a P/E ratio of -23.75 and a beta of 0.98. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. During the same period last year, the firm earned ($0.57) earnings per share. Mirum Pharmaceuticals’s quarterly revenue was up 89.4% on a year-over-year basis. On average, research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Amalgamated Bank increased its position in Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after purchasing an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after buying an additional 318 shares during the period. Avanza Fonder AB bought a new position in Mirum Pharmaceuticals in the fourth quarter worth about $189,000. ProShare Advisors LLC purchased a new stake in Mirum Pharmaceuticals in the second quarter worth about $213,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at approximately $215,000.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on MIRM shares. HC Wainwright reiterated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Leerink Partners raised their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Citigroup boosted their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.